MedWire News: Users of the injectable contraceptive depot-medroxyprogesterone acetate (DMPA) are nearly four times more likely to develop venous thromboembolism (VTE) than nonusers of hormonal contraceptives, study findings indicate.
MedWire News: Users of the injectable contraceptive depot-medroxyprogesterone acetate (DMPA) are nearly four times more likely to develop venous thromboembolism (VTE) than nonusers of hormonal contraceptives, study findings indicate.